Dr. Edmund S Kopetz

Claim this profile
Studies Colorectal Cancer
Studies Stomach Cancer
1 reported clinical trial
3 drugs studied

Area of expertise

1Colorectal Cancer
Edmund S Kopetz has run 1 trial for Colorectal Cancer. Some of their research focus areas include:
Stage IV
BRAF positive
2Stomach Cancer
Edmund S Kopetz has run 1 trial for Stomach Cancer. Some of their research focus areas include:
Stage IV
BRAF positive

Clinical Trials Edmund S Kopetz is currently running

Image of trial facility.

ZEN003694 + Chemotherapy

for Colorectal Cancer

This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory), that has come back after a period of improvement (relapsed), and that has spread from where it first started (primary site) to other places in the body (metastatic). ZEN003694 is a protein inhibitor that binds to BET proteins. When ZEN003694 binds to BET proteins, it disrupts gene expression. Preventing the expression of certain growth-promoting genes may inhibit proliferation of tumor cells that over-express BET proteins. Immunotherapy with monoclonal antibodies, such as cetuximab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Encorafenib is an enzyme inhibitor. It inhibits pathways that are responsible for controlling cell proliferation and survival, which may lead to a decrease in tumor cell proliferation. Both cetuximab and encorafenib have been approved to treat cancer. Adding ZEN003694 to cetuximab and encorafenib may be more effective at treating patients with refractory metastatic colorectal cancer than giving the usual treatment (cetuximab and encorafenib) alone.
Recruiting1 award Phase 1

More about Edmund S Kopetz

Clinical Trial Related1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Edmund S Kopetz has experience with
  • Cetuximab
  • Encorafenib
  • ZEN003694
Breakdown of trials Edmund S Kopetz has run
Colorectal Cancer
Stomach Cancer
Colon Cancer
Colorectal Adenocarcinoma

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Edmund S Kopetz specialize in?
Edmund S Kopetz focuses on Colorectal Cancer and Stomach Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are BRAF positive.
Is Edmund S Kopetz currently recruiting for clinical trials?
Yes, Edmund S Kopetz is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Edmund S Kopetz has studied deeply?
Yes, Edmund S Kopetz has studied treatments such as Cetuximab, Encorafenib, ZEN003694.
What is the best way to schedule an appointment with Edmund S Kopetz?
Apply for one of the trials that Edmund S Kopetz is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top